Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Terminated
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2013
Locations: Pfizer Investigational Site, Columbus, Mississippi +4 locations
Conditions: Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Completed
To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2013
Locations: Pfizer Investigational Site, Columbus, Mississippi +5 locations
Conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Completed
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2013
Locations: Pfizer Investigational Site, Corinth, Mississippi +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of doxorubicin and cisplatin with or without paclitaxel and G-CSF in treating patients who have stage III, stage IV, or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2013
Locations: University of Mississippi Medical Center, Jackson, Mississippi +1 locations
Conditions: Endometrial Cancer
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients with previously untreated stage III or stage IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
07/08/2013
Locations: University of Mississippi Medical Center, Jackson, Mississippi +1 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of paclitaxel and cisplatin with or without surgery in treating patients with stage III ovarian epithelial cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
07/08/2013
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Ovarian Cancer
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin plus paclitaxel with or without tirapazamine in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Veterans Affairs Medical Center - Biloxi, Biloxi, Mississippi +3 locations
Conditions: Lung Cancer
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin plus fluorouracil are more effective than paclitaxel plus cisplatin in treating patients with advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients with advanced head and neck cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Veterans Affairs Medical Center - Biloxi, Biloxi, Mississippi +3 locations
Conditions: Head and Neck Cancer
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with advanced, refractory, or recurrent cervical or vaginal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
06/19/2013
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Cervical Cancer, Vaginal Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus hormone therapy in treating patients who have... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/12/2013
Locations: University of Mississippi Medical Center, Jackson, Mississippi +1 locations
Conditions: Prostate Cancer
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2013
Locations: Veterans Affairs Medical Center - Biloxi, Biloxi, Mississippi +2 locations
Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have stage III or stage IV ovarian epithelial or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/24/2013
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer